AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland - Candlesense
AIM Clinical trials

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

(AIM) Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here

Related Questions

How robust are the Ampligen pancreatic cancer trial results and what are the next regulatory milestones? What is the estimated market opportunity for Ampligen in pancreatic cancer relative to existing therapies? How might this data release affect AIM ImmunoTech's short‑term stock volatility and trading volume?
Find similar articles on Candlesense globenewswire